Quick reference for the intranasal Selank 5 mg calculation.

• Human research route: Intranasal drops or solution.

• Peptide amount: 5,000 mcg total in the vial.

• 5 mL option: 1,000 mcg/mL and 100 mcg per verified 0.10 mL spray.

• 10 mL option: 500 mcg/mL and 50 mcg per verified 0.10 mL spray.

• Final-volume rule: Bring the transferred solution to an exact measured final volume.

Storage depends on the complete formulation, container, and handling method.
• Registered 0.15% product: Protected from light, stored at no more than 10 degrees C, and not frozen[5].
• Opened registered product: The manufacturer permits storage at no more than 25 degrees C for up to 15 days[5].
• Custom research preparation: Use formulation-specific stability and microbiological controls rather than transferring the finished-product shelf life.
• Labeling: Record preparation date, final volume, concentration, vehicle, and storage conditions.

Selank is a synthetic heptapeptide based on the tuftsin sequence. Human studies have examined anxiety-related clinical measures, leu-enkephalin metabolism, EEG response patterns, and functional brain connectivity after Selank exposure[1][2][4]. Intranasal drops or solution are the delivery methods reported in the primary human research summarized on this page.
The vial calculation is concentration based. Dividing 5,000 mcg by the measured final volume gives mcg per mL. Multiplying that concentration by the verified pump output gives mcg per spray.

Selank findings should be interpreted in the context of the study population, formulation, and study design.

• The 2008 comparative study reported anxiety-related effects for Selank and medazepam, with additional anti-asthenic and psychostimulant observations in the Selank group[1].

• In the 2012 generalized anxiety disorder study, participants showed both rapid and more gradual response patterns over the study period[2].

• The healthy-volunteer neuroimaging study examined functional connectivity following intranasal Selank exposure rather than a repeated clinical treatment course[3].

• The current manufacturer information lists unpleasant taste sensations and possible allergic reactions among reported adverse effects[4].

• Nasal formulation, device performance, nasal conditions, and administration variables can affect delivered amount and deposition characteristics[5][6].

Human Selank research has primarily used the intranasal route. The studies below show the reported amount, formulation, and research setting so visitors can compare the literature without treating different protocols as interchangeable.
Source | Research Context | Published Intranasal Amount and Formulation
Zozulia et al., 2008[1] | 62 adults with generalized anxiety disorder or neurasthenia | Selank 0.15% nasal drops at 2.7 mg per day, reported as 36 drops divided across three administrations, with outcomes followed through day 14.
Syunyakov et al., 2012[2] | 20 adults with generalized anxiety disorder | 2,700 mcg per day intranasally. The pharmaco-EEG analysis also examined a single 900 mcg exposure.
Panikratova et al., 2020[4] | Healthy-volunteer functional connectivity study | One intranasal exposure using 0.15% Selank solution, 60 microliters per nostril, described as a 0.2 mg total amount.
The current manufacturer instruction describes a 0.15% nasal-drop product at 1.5 mg/mL, with two drops placed in each nasal passage three times daily for 14 days[5]. Those drop counts belong to the registered bottle and finished formulation. They are not direct equivalents to a different metered pump.
Reference concentration: Mathematically, 5 mg brought to about 3.33 mL equals 1.5 mg/mL. A verified 0.10 mL actuation at that concentration contains 150 mcg. This is a concentration comparison, not a reproduction of the registered preserved drop product.